Clinical Consequence of CBP Gene Mutation
Authors:
J. Šmardová; J. Šmarda 1
Authors‘ workplace:
Oddělení buněčné a molekulární onkologie, Masarykův onkologický ústav, Brno 1 Katedra genetiky a molekulární biologie, Přírodovědecká fakulta Masarykovy univerzity, Brno
Published in:
Čas. Lék. čes. 1999; : 739-743
Category:
Overview
Gene CBP codes for a transcriptional coactivator, which can interact with many transcriptional factors. It modifiesthe process of transcription stimulated by these factors by specific binding to RNA polymerase II holoenzyme or byhistone acetylation. CBP gene mutation is the molecular cause of autosomal dominant genetic disease calledRubinstein-Taybi syndrome that is manifested by mental and growth retardations, by typical face malformations andbroad thumbs and broad big toes. The CBP gene can be affected by the t(8;16)(p11;p13.3) translocation resulting inproduction of the MOZ/CBP chimeric protein and in induction of acute myeloblastic leukaemia. Therapy usingtopoisomerase II inhibitors can induce the t(11;16)(q23;13.3) translocation causing acute myeloid or lymphoidleukaemia or myelodysplasia through production of the MLL/CBP protein chimera.
Key words:
CBP, Rubinstein-Taybi syndrome, leukaemia, t(8;16), t(11;16).
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- On the Equipotency of Vitamin D2 and D3 in Man
- Clinical Consequence of CBP Gene Mutation
- Continence Following Radical Retropubic Prostatectomy
- Influence of Partial Realimentation on Serum Leptin Levels andResting Energy Expenditure in Patients with Anorexia Nervosa